Sperogenix In-licenses Rare Disease Treatment in $124 Million Deal
publication date: Jan 4, 2022
Sperogenix Therapeutics, a Beijing rare disease company, in-licensed China rights to vamorolone for rare disease indications from Switzerland's Santhera in a deal valued at up to $124 million, plus royalties. Initially, Sperogenix will develop the drug in China for Duchenne muscular dystrophy, a genetic disease. Santhera is conducting US tests of the drug, with plans to start a rolling submission in Q1 of 2022. In 2019, Sperogenix was formed by Lilly Asia Ventures and Morningside Venture Capital to bring rare diseases therapies to China. More details....
Stock Symbol: (SIX: SANN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.